Rankings
▼
Calendar
UTHR Q4 2025 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena
UTHR
United Therapeutics Corporation
$24B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$790M
+7.4% YoY
Gross Profit
$687M
86.9% margin
Operating Income
$357M
45.1% margin
Net Income
$364M
46.1% margin
EPS (Diluted)
$7.66
QoQ Revenue Growth
-1.2%
Cash Flow
Operating Cash Flow
$346M
Free Cash Flow
$173M
Stock-Based Comp.
$39M
Balance Sheet
Total Assets
$7.9B
Total Liabilities
$784M
Stockholders' Equity
$7.1B
Cash & Equivalents
$1.6B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$790M
$736M
+7.4%
Gross Profit
$687M
$660M
+4.1%
Operating Income
$357M
$358M
-0.3%
Net Income
$364M
$301M
+20.9%
Revenue Segments
Tyvaso
$464M
59%
Remodulin
$128M
16%
Orenitram
$121M
15%
Unituxin
$62M
8%
Adcirca
$8M
1%
Product and Service, Other
$7M
1%
Geographic Segments
UNITED STATES
$753M
95%
Non-US
$37M
5%
← FY 2025
All Quarters